Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDOXYCYCLINE (doxycycline) by Pfizer is 12. Approved for only inflammatory lesions (papules, pustules) of rosacea in adult patients, development of drug-resistant bacteria and 1 more indications. First approved in 2024.
Drug data last refreshed 20h ago
12.1 Mechanism of Action The mechanism of action of doxycycline in the treatment of inflammatory lesions of rosacea is unknown. 12.3 Pharmacokinetics Doxycycline capsules are not bioequivalent to other doxycycline products. The pharmacokinetics of doxycycline following oral administration of…
Worked on DOXYCYCLINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Tetracycline-class Drug
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
Doxycycline vs. Macrolide for MRMP (DOMINO)
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya
A Study of Doxycycline to Treat Chlamydial Infection
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo